Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $36.00 Average PT from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $35.75.

ARCT has been the subject of several recent analyst reports. Guggenheim cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright lowered their target price on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Finally, Citigroup reduced their price target on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. CANADA LIFE ASSURANCE Co grew its stake in shares of Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares in the last quarter. Brevan Howard Capital Management LP purchased a new position in Arcturus Therapeutics during the 3rd quarter valued at about $518,000. Bank of America Corp DE grew its position in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after acquiring an additional 327,626 shares in the last quarter. Two Sigma Investments LP grew its position in Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after acquiring an additional 2,857 shares in the last quarter. Finally, Kennedy Capital Management LLC increased its stake in Arcturus Therapeutics by 95.5% during the third quarter. Kennedy Capital Management LLC now owns 22,825 shares of the biotechnology company’s stock worth $421,000 after purchasing an additional 11,151 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Arcturus Therapeutics Trading Up 3.8%

Arcturus Therapeutics stock opened at $6.61 on Friday. The company has a 50-day moving average price of $7.18 and a 200 day moving average price of $13.16. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The stock has a market cap of $187.79 million, a P/E ratio of -2.69 and a beta of 2.24.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.60. The company had revenue of $17.15 million for the quarter, compared to analyst estimates of $17.47 million. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. As a group, analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.